CN104725309A - PTP1B inhibitor containing nicotinic acid amide structure and use thereof - Google Patents

PTP1B inhibitor containing nicotinic acid amide structure and use thereof Download PDF

Info

Publication number
CN104725309A
CN104725309A CN201510108698.3A CN201510108698A CN104725309A CN 104725309 A CN104725309 A CN 104725309A CN 201510108698 A CN201510108698 A CN 201510108698A CN 104725309 A CN104725309 A CN 104725309A
Authority
CN
China
Prior art keywords
compound
ptp1b inhibitor
acid amide
nicotinic acid
ptp1b
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510108698.3A
Other languages
Chinese (zh)
Inventor
蔡子洋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Foshan Saiweisi Pharmaceutical Technology Co Ltd
Original Assignee
Foshan Saiweisi Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foshan Saiweisi Pharmaceutical Technology Co Ltd filed Critical Foshan Saiweisi Pharmaceutical Technology Co Ltd
Priority to CN201510108698.3A priority Critical patent/CN104725309A/en
Priority to CN201710074715.5A priority patent/CN106748998A/en
Publication of CN104725309A publication Critical patent/CN104725309A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to the field of medicines related to type II diabetes and particularly relates to a PTP1B inhibitor containing a nicotinic acid amide structure, a preparation method thereof and application of the PTP1B inhibitor in preparation of medicines for treating the type II diabetes. The PTP1B inhibitor has a structure represented by a formula shown in descriptions.

Description

A kind of PTP1B inhibitor containing niacin hydroxyacyl amine structure and uses thereof
Technical field
The present invention relates to the pharmaceutical field of type ii diabetes treatment.More particularly, the present invention relates to type ii diabetes tool medicative a kind of PTP1B inhibitor, its preparation method containing niacin hydroxyacyl amine structure, and the purposes in pharmacy.
Background technology
Type ii diabetes is a kind of common metabolic disturbance diseases, it is characterized in that periphery produces resistant function to film island element, shows as Regular Insulin to be combined signal transduction afterwards with insulin receptor and to lack at molecular level.The phosphorylation level of proteolytic enzyme propylhomoserin is the important regulate factors of intracellular signal transduction, it is by proteolytic enzyme histidine kinase (protein tyrosine kinase, PTK) and proteolytic enzyme propylhomoserin Phosphoric acid esterase (protein tyrosine phosphatase, PTP) jointly regulate and control.Research in recent years finds, proteolytic enzyme propylhomoserin phosphatase 1 B can dephosphorylation proteolytic enzyme propylhomoserin, plays important negative regulation effect in Insulin signaling pathway.Knock out PTPIB gene, or use antisense core former times acid (ASO) to suppress the expression of PTP1B albumen and mRNA in body, not only can significantly improve the susceptibility of test mice to Regular Insulin, and obviously can reduce the ill probability of obesity.These researchs show, PTP1B likely becomes the novel targets for the treatment of type ii diabetes.
The invention discloses a kind of PTP1B inhibitor containing niacin hydroxyacyl amine structure of novel structure, these compounds can be used for the medicine preparing treatment type ii diabetes.
Summary of the invention
An object of the present invention is to provide a kind of PTP1B inhibitor with the excellent activity of formula I.
Another object of the present invention is to provide the method that preparation has the compound of formula I.
The compound that another object of the present invention is to provide containing formula I is treating the application in type ii diabetes as effective constituent.
Now in conjunction with object of the present invention, content of the present invention is specifically described.
The compound that the present invention has formula I has following structural formula:
Formula I of the present invention is synthesized by following route:
Compound II per in the presence of a base with compound III generation substitution reaction, obtain compound IV; There is lower and compound V at DCC (N, N'-dicyclohexyl carbodiimide) and react in compound IV, obtains VI; The oxidation of oxidized dose of compound VI, obtains Compound I.Compound II per can prepare (Leon Katz according to literature method; Et al, Journal of Organic Chemistry, 1954,19,711).
Formula I of the present invention has the restraining effect of PTP1B, can be used as effective constituent for the preparation of type ii diabetes medicine.The activity of formula I of the present invention is verified by receptor binding assays.
Formula I of the present invention is effective in quite wide dosage range.The dosage that such as every day takes, within the scope of 1mg-1000mg/ people, is divided into once or administration for several times.The actual dosage taking formula I can be decided according to relevant situation by doctor.
Embodiment
Below in conjunction with embodiment, the present invention is further illustrated.It should be noted that, following embodiment be only for illustration of, and not for limiting the present invention.The various changes that those skilled in the art's training centre according to the present invention is made all should within the protection domain required by the application's claim.
the synthesis of embodiment 1 Compound I
A. the synthesis of compound IV-1
Compound II per (1.55g, 10mmol), compound III-1 (2.16g, 10mmol) and solid K 2cO 3(5.53g, 40mmol) adds in the DMF of 30mL drying, room temperature for overnight, and TLC follows the tracks of and finds that reaction completes.Reaction mixture pours in 200mL frozen water, stirs, regulates pH=4-5, use CH with concentrated hydrochloric acid 2cl 2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound IV-1, white solid.ESI-MS,m/z＝289([M-H] -)。
B. the synthesis of compound VI-1
Compound IV-1 (1.45g, 5mmol), compound V-1 (0.43g, 5mmol), DCC (1.24g, 6mmol) with DMAP (DMAP, 0.3g) be dissolved in dry 20mL THF, room temperature for overnight, TLC follows the tracks of and finds that reaction completes.Reaction mixture pours in 200mL frozen water, stirs, uses CH 2cl 2(60mL × 3) extract, and merge extraction phase, use 2% dilute hydrochloric acid and salt water washing successively, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound VI-1, white solid.ESI-MS,m/z＝358([M+H] +)。
C. the synthesis of Compound I
Compound VI-1 (0.71g, 2mmol) is dissolved in 10mL CH 2cl 2in, stirred at ambient temperature, add metachloroperbenzoic acid (mCPBA, 1.72g, 10mmol), reaction mixture at room temperature stirs 1 hour, then temperature rising reflux 3 hours, and TLC detection reaction completes.Reaction mixture pours in 200mL frozen water, stirs, uses CH 2cl 2(60mL × 3) extract, and merge extraction phase, use saturated NaHCO successively 3solution and salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains Compound I, white solid.ESI-MS，m/z＝406([M+H] +)。
the synthesis of embodiment 2 reference compound R-1
In order to pharmacological effect more of the present invention further, applicant describes the unknown compound R-1 (not yet open) being all applicant's invention in this application.
A. the synthesis of compound IV-2
Compound II per (1.55g, 10mmol), compound III-2 (1.71g, 10mmol) and solid K 2cO 3(5.53g, 40mmol) adds in the DMF of 30mL drying, room temperature for overnight, and TLC follows the tracks of and finds that reaction completes.Reaction mixture pours in 200mL frozen water, stirs, regulates pH=4-5, use CH with concentrated hydrochloric acid 2cl 2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound IV-2, white solid.ESI-MS,m/z＝244([M-H] -)。
B. the synthesis of compound VI-2
Compound IV-2 (1.23g, 5mmol), compound V-1 (0.43g, 5mmol), DCC (1.24g, 6mmol) with DMAP (DMAP, 0.3g) be dissolved in dry 20mL THF, room temperature for overnight, TLC follows the tracks of and finds that reaction completes.Reaction mixture pours in 200mL frozen water, stirs, uses CH 2cl 2(60mL × 3) extract, and merge extraction phase, use 2% dilute hydrochloric acid and salt water washing successively, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound VI-2, white solid.ESI-MS,m/z＝313([M+H] +)。
C. the synthesis of compound R-1
Compound VI-2 (0.62g, 2mmol) is dissolved in 10mL CH 2cl 2in, stirred at ambient temperature, add metachloroperbenzoic acid (mCPBA, 1.72g, 10mmol), reaction mixture at room temperature stirs 1 hour, then temperature rising reflux 3 hours, and TLC detection reaction completes.Reaction mixture pours in 200mL frozen water, stirs, uses CH 2cl 2(60mL × 3) extract, and merge extraction phase, use saturated NaHCO successively 3solution and salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound R-1, white solid.ESI-MS，m/z＝361([M+H] +)。
embodiment 3 Compound ira vitro is to the inhibition test of PTP1B
Be that the compound solution 95%DMSO of 50mM carries out 1/2 gradient dilution by original concentration, dilute 11 concentration gradients altogether.Enzyme reaction system alive amounts to 102 μ L, and wherein compound adds volume is 2 μ L.First, in 96 orifice plates, add 50 μ L PTP1B albumen successively, the testing compound of 2 μ L different concns, concussion 1min, hatches 30min for 30 DEG C, then adds 50 μ L pNPP (para-nitro-pheneye phosphate), concussion 10s.Under mensuration 405nm wavelength, absorbancy is with the change in reaction times, within 6 seconds, survey once, survey 60 points, replicate(determination) three times, and draw out reaction process curve, thus under calculating different concns each compound to the inhibit activities of enzyme, software GraphPad Prism 5 software is utilized to carry out non linear fit analysis, with remaining activity value for ordinate zou, compound concentration logarithmic value is X-coordinate curve plotting, calculates the IC of this compound 50value.
Test result sees the following form.
Compound IC 50(nM)
Reference compound R-1 18.6
The compounds of this invention I 7.1
As can be seen from upper table result, compound of the present invention has very strong restraining effect to PTP1B, can as preparation treatment type ii diabetes medicine.

Claims (2)

1. a compound for formula I structure,
2. the application of the described formula I of one of claim 1 in preparation treatment diabetes B medicine.
CN201510108698.3A 2015-03-12 2015-03-12 PTP1B inhibitor containing nicotinic acid amide structure and use thereof Pending CN104725309A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201510108698.3A CN104725309A (en) 2015-03-12 2015-03-12 PTP1B inhibitor containing nicotinic acid amide structure and use thereof
CN201710074715.5A CN106748998A (en) 2015-03-12 2015-03-12 A kind of PTP1B inhibitor containing niacin hydroxyacyl amine structure and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510108698.3A CN104725309A (en) 2015-03-12 2015-03-12 PTP1B inhibitor containing nicotinic acid amide structure and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710074715.5A Division CN106748998A (en) 2015-03-12 2015-03-12 A kind of PTP1B inhibitor containing niacin hydroxyacyl amine structure and application thereof

Publications (1)

Publication Number Publication Date
CN104725309A true CN104725309A (en) 2015-06-24

Family

ID=53449790

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510108698.3A Pending CN104725309A (en) 2015-03-12 2015-03-12 PTP1B inhibitor containing nicotinic acid amide structure and use thereof
CN201710074715.5A Pending CN106748998A (en) 2015-03-12 2015-03-12 A kind of PTP1B inhibitor containing niacin hydroxyacyl amine structure and application thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710074715.5A Pending CN106748998A (en) 2015-03-12 2015-03-12 A kind of PTP1B inhibitor containing niacin hydroxyacyl amine structure and application thereof

Country Status (1)

Country Link
CN (2) CN104725309A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
WO2002018321A2 (en) * 2000-08-29 2002-03-07 Abbott Laboratories Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors
CN101123964A (en) * 2004-12-24 2008-02-13 普罗西迪恩有限公司 G-protein coupled receptor(GPR116) agonists and use thereof for treating obesity and diabetes
CN101484440A (en) * 2006-07-06 2009-07-15 艾尼纳制药公司 Modulators of metabolism and the treatment of disorders related thereto

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
WO2002018321A2 (en) * 2000-08-29 2002-03-07 Abbott Laboratories Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors
CN101123964A (en) * 2004-12-24 2008-02-13 普罗西迪恩有限公司 G-protein coupled receptor(GPR116) agonists and use thereof for treating obesity and diabetes
CN101484440A (en) * 2006-07-06 2009-07-15 艾尼纳制药公司 Modulators of metabolism and the treatment of disorders related thereto

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李升康 等: "蛋白酪氨酸磷酸酶1B (PTP-1B)在2 型糖尿病治疗中的研究进展", 《衡阳师范学院学报》 *

Also Published As

Publication number Publication date
CN106748998A (en) 2017-05-31

Similar Documents

Publication Publication Date Title
Zhang et al. A novel small-molecule disrupts Stat3 SH2 domain–phosphotyrosine interactions and Stat3-dependent tumor processes
CN102260190B (en) N-benzyl-N'-(terminal carboxylic acid substituted acyloxy)octanediamide compounds with anti-tumor effect and pharmaceutical salts thereof
Guo et al. Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors
CN101973989B (en) Thiazole amide compound and medicinal application thereof for treating malignancy
CN104725309A (en) PTP1B inhibitor containing nicotinic acid amide structure and use thereof
CN104725310A (en) PTP1B inhibitor containing nicotinic acid amide and aniline structures and use thereof
CN104725307A (en) PTP1B inhibitor containing nicotinic acid amide structure and preparation method and use thereof
CN104725355A (en) PTP1B inhibitor containing nicotinic acid amide and piperidine structures and use thereof
CN104725312A (en) PTP1B inhibitor containing nicotinic acid amide and aniline structures and preparation method and use thereof
CN104761540A (en) Compound containing structures of nicotinamide and piperidine and application thereof
CN104725353A (en) PTP1B inhibitor containing nicotinic acid amide and piperidine structures and use thereof
CN104725354A (en) Compound containing nicotinic acid amide and piperidine structures and use thereof
CN104725308A (en) PTP1B inhibitor containing nicotinic acid amide structure and preparation method and use thereof
CN104725306A (en) PTP1B inhibitor containing nicotinic acid amide structure and preparation method and use thereof
CN104725311A (en) PTP1B inhibitor containing nicotinic acid amide structure and use thereof
CN104788424A (en) PTP1B inhibitors containing nicotinamide and piperidine structure, and preparation method and use thereof
CN104788425A (en) PTP1B inhibitors containing nicotinamide and piperidine structure, and preparation method and use thereof
CN104744386A (en) PTP1B inhibitor containing tetrazole structure and use of PTP1B inhibitor
CN104744387A (en) PTP1B inhibitor containing tetrazole and halobenzene structures, preparation method of PTP1B inhibitor and use of PTP1B inhibitor
CN104803932A (en) PTP (protein tyrosine phosphatase)1B inhibitors containing tetrazole structures and application of PTP1B inhibitors
CN104803933A (en) PTP1B inhibitors containing tetrazole structures as well as preparation methods and applications of inhibitors
CN104803977A (en) PTP1B derivatives containing tetrazole structures as well as preparation methods and applications of derivatives
CN104744385A (en) PTP1B inhibitor containing tetrazole structure and use of PTP1B inhibitor
CN104744388A (en) PTP1B inhibitor containing tetrazole structure, preparation method of PTP1B inhibitor and use of PTP1B inhibitor
CN104803931A (en) PTP (protein tyrosine phosphatase)1B inhibitors containing tetrazole structure as well as preparation methods and application of PTP1B inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150624